A New Dawn in Alzheimer's Fight? Radical Drug Shows 'Meaningful Improvement' in Cognition

A novel drug, masitinib, is rewriting the rules for Alzheimer's treatment by targeting the brain's immune system, a fundamentally new approach.
In a major clinical study, patients with mild Alzheimer's didn't just see their decline slow—they showed a "meaningful improvement" in cognitive function over 24 weeks.
New independent research confirms the drug's potential, showing it reduces toxic proteins, protects vital brain connections, and suppresses devastating neuroinflammation.

In the relentless battle against Alzheimer's disease, a condition that robs millions of their memories and futures, a groundbreaking development offers a powerful new ray of hope. A new peer-reviewed study, accessible here, has provided compelling evidence for masitinib, a drug that takes a radically different approach to fighting the disease¹.

Unlike most therapies focused on amyloid plaques, masitinib targets the brain’s own innate immune system—specifically the mast cells and microglia that can fuel a destructive inflammatory storm in the Alzheimer's brain [1, 7]. The results are stunning. In a study mimicking sporadic Alzheimer's, which accounts for over 95% of cases, masitinib didn't just slow the damage; it reversed key symptoms. Mice treated with the drug showed marked improvements in memory, learning, and even sense of smell—an early indicator of the disease's progression¹.

These findings build on jaw-dropping clinical data from a completed Phase 2B/3 study. While most treatments aim to simply stall cognitive decline, masitinib demonstrated a significant improvement in cognitive function for patients with mild Alzheimer's over a 24-week period [3, 4]. The treatment arm showed a meaningful cognitive gain, while the control group remained stable¹.

By reducing toxic tau proteins, protecting essential brain synapses, and calming the neuroinflammatory cascade, masitinib offers a dual-pronged attack of cognitive enhancement and neuroprotection⁷. With a large-scale Phase 3 trial now authorized by the FDA and European agencies, AB Science is on the cusp of potentially delivering a transformative therapy, secured by patent protection until 2041 [1, 2].

A New Dawn in Alzheimer's Fight? Radical Drug Shows 'Meaningful Improvement' in Cognition

References

Stay Updated!